Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 7.45 CHF 0.95% Market Closed
Market Cap: 141.9m CHF
Have any thoughts about
Newron Pharmaceuticals SpA?
Write Note

Intrinsic Value

The intrinsic value of one NWRN stock under the Base Case scenario is 3.1 CHF. Compared to the current market price of 7.45 CHF, Newron Pharmaceuticals SpA is Overvalued by 58%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NWRN Intrinsic Value
3.1 CHF
Overvaluation 58%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Newron Pharmaceuticals SpA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for NWRN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about NWRN?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Newron Pharmaceuticals SpA

Provide an overview of the primary business activities
of Newron Pharmaceuticals SpA.

What unique competitive advantages
does Newron Pharmaceuticals SpA hold over its rivals?

What risks and challenges
does Newron Pharmaceuticals SpA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Newron Pharmaceuticals SpA.

Provide P/S
for Newron Pharmaceuticals SpA.

Provide P/E
for Newron Pharmaceuticals SpA.

Provide P/OCF
for Newron Pharmaceuticals SpA.

Provide P/FCFE
for Newron Pharmaceuticals SpA.

Provide P/B
for Newron Pharmaceuticals SpA.

Provide EV/S
for Newron Pharmaceuticals SpA.

Provide EV/GP
for Newron Pharmaceuticals SpA.

Provide EV/EBITDA
for Newron Pharmaceuticals SpA.

Provide EV/EBIT
for Newron Pharmaceuticals SpA.

Provide EV/OCF
for Newron Pharmaceuticals SpA.

Provide EV/FCFF
for Newron Pharmaceuticals SpA.

Provide EV/IC
for Newron Pharmaceuticals SpA.

Show me price targets
for Newron Pharmaceuticals SpA made by professional analysts.

What are the Revenue projections
for Newron Pharmaceuticals SpA?

How accurate were the past Revenue estimates
for Newron Pharmaceuticals SpA?

What are the Net Income projections
for Newron Pharmaceuticals SpA?

How accurate were the past Net Income estimates
for Newron Pharmaceuticals SpA?

What are the EPS projections
for Newron Pharmaceuticals SpA?

How accurate were the past EPS estimates
for Newron Pharmaceuticals SpA?

What are the EBIT projections
for Newron Pharmaceuticals SpA?

How accurate were the past EBIT estimates
for Newron Pharmaceuticals SpA?

Compare the revenue forecasts
for Newron Pharmaceuticals SpA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Newron Pharmaceuticals SpA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Newron Pharmaceuticals SpA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Newron Pharmaceuticals SpA compared to its peers.

Compare the P/E ratios
of Newron Pharmaceuticals SpA against its peers.

Discuss the investment returns and shareholder value creation
comparing Newron Pharmaceuticals SpA with its peers.

Analyze the financial leverage
of Newron Pharmaceuticals SpA compared to its main competitors.

Show all profitability ratios
for Newron Pharmaceuticals SpA.

Provide ROE
for Newron Pharmaceuticals SpA.

Provide ROA
for Newron Pharmaceuticals SpA.

Provide ROIC
for Newron Pharmaceuticals SpA.

Provide ROCE
for Newron Pharmaceuticals SpA.

Provide Gross Margin
for Newron Pharmaceuticals SpA.

Provide Operating Margin
for Newron Pharmaceuticals SpA.

Provide Net Margin
for Newron Pharmaceuticals SpA.

Provide FCF Margin
for Newron Pharmaceuticals SpA.

Show all solvency ratios
for Newron Pharmaceuticals SpA.

Provide D/E Ratio
for Newron Pharmaceuticals SpA.

Provide D/A Ratio
for Newron Pharmaceuticals SpA.

Provide Interest Coverage Ratio
for Newron Pharmaceuticals SpA.

Provide Altman Z-Score Ratio
for Newron Pharmaceuticals SpA.

Provide Quick Ratio
for Newron Pharmaceuticals SpA.

Provide Current Ratio
for Newron Pharmaceuticals SpA.

Provide Cash Ratio
for Newron Pharmaceuticals SpA.

What is the historical Revenue growth
over the last 5 years for Newron Pharmaceuticals SpA?

What is the historical Net Income growth
over the last 5 years for Newron Pharmaceuticals SpA?

What is the current Free Cash Flow
of Newron Pharmaceuticals SpA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Newron Pharmaceuticals SpA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Newron Pharmaceuticals SpA

Current Assets 19.7m
Cash & Short-Term Investments 12.6m
Receivables 5.2m
Other Current Assets 1.9m
Non-Current Assets 6.2m
PP&E 405k
Other Non-Current Assets 5.8m
Current Liabilities 28.9m
Accounts Payable 2m
Accrued Liabilities 3.5m
Other Current Liabilities 23.4m
Non-Current Liabilities 26.8m
Long-Term Debt 26m
Other Non-Current Liabilities 885k
Efficiency

Earnings Waterfall
Newron Pharmaceuticals SpA

Revenue
9.1m EUR
Cost of Revenue
-471k EUR
Gross Profit
8.6m EUR
Operating Expenses
-20.2m EUR
Operating Income
-11.6m EUR
Other Expenses
-4.6m EUR
Net Income
-16.2m EUR

Free Cash Flow Analysis
Newron Pharmaceuticals SpA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

NWRN Profitability Score
Profitability Due Diligence

Newron Pharmaceuticals SpA's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional ROE
Exceptional Revenue Growth Forecast
ROE is Increasing
37/100
Profitability
Score

Newron Pharmaceuticals SpA's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

NWRN Solvency Score
Solvency Due Diligence

Newron Pharmaceuticals SpA's solvency score is 29/100. The higher the solvency score, the more solvent the company is.

Low D/E
Positive Net Debt
Short-Term Solvency
Long-Term Solvency
29/100
Solvency
Score

Newron Pharmaceuticals SpA's solvency score is 29/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NWRN Price Targets Summary
Newron Pharmaceuticals SpA

Wall Street analysts forecast NWRN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NWRN is 14.08 CHF with a low forecast of 12.93 CHF and a high forecast of 15.75 CHF.

Lowest
Price Target
12.93 CHF
74% Upside
Average
Price Target
14.08 CHF
89% Upside
Highest
Price Target
15.75 CHF
111% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for NWRN?

Click here to dive deeper.

Dividends

Newron Pharmaceuticals SpA
does not pay dividends
Shareholder Yield

Current shareholder yield for NWRN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA

Country

Italy

Industry

Pharmaceuticals

Market Cap

132.9m CHF

Dividend Yield

0%

Description

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 25 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

Contact

MILANO
Bresso
Via Ludovico Ariosto 21
+39026103461.0
www.newron.com

IPO

2006-12-12

Employees

25

Officers

CEO & Executive Director
Mr. Stefan Weber
Chief Financial Officer
Mr. Roberto Galli
Vice President of Operations
Mr. Filippo Moriggia
Chief Medical Officer
Dr. Ravi Anand M.D., Ph.D.
Vice President of Business Development
Ms. Laura Faravelli

See Also

Discover More
What is the Intrinsic Value of one NWRN stock?

The intrinsic value of one NWRN stock under the Base Case scenario is 3.1 CHF.

Is NWRN stock undervalued or overvalued?

Compared to the current market price of 7.45 CHF, Newron Pharmaceuticals SpA is Overvalued by 58%.

Back to Top